Orforglipron + B6 1mg
Orforglipron + B6 1mg is a prescriber-directed weight-management medication option. It should be used as part of a broader care plan that includes nutrition, activity, contraindication screening, and monitoring.
This preparation provides orforglipron at its lowest formulated dose — 1 mg — combined with pyridoxine (vitamin B6) for patients requiring a gradual, low-threshold introduction to GLP-1 receptor agonist therapy. The 1 mg dose is intended for patients with GI sensitivity, those re-initiating after intolerance, or those in whom an extended slow-ramp protocol has been prescribed. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded oral capsule; it is not FDA-approved as a compounded preparation.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Orforglipron 1 mg | Non-peptide GLP-1 receptor agonist (small molecule); ultra-low initiation dose used to acclimate the GI and CNS to GLP-1R agonism with minimal adverse effects before dose escalation. |
| Pyridoxine (Vitamin B6) — per prescriber order | B-complex vitamin with antiemetic properties; co-formulated to reduce GLP-1 class-associated nausea at the lowest dose tier. |
Oral capsule: Swallow intact with water, with or without food. No fasting requirement. Take at the same time each day for consistent plasma levels. Do not crush or open the capsule unless directed.
The 1 mg dose is an ultra-low initiation tier for patients who require maximal GI caution during GLP-1R agonist introduction.
- Initiation: 1 mg/day; prescriber determines the duration at this dose and the subsequent escalation steps (e.g., 1 mg → 3 mg → 12 mg → 24 mg → 36 mg over weeks to months).
- Pyridoxine (B6): Included for antiemetic support; dose is prescriber-specified.
- All dose adjustments and the escalation schedule are determined solely by the prescriber.
- Orforglipron: Full GLP-1 receptor agonist; non-peptide, small-molecule structure confers oral bioavailability and resistance to DPP-4 degradation. Even at low receptor occupancy (1 mg dose), partial pharmacodynamic activity occurs at GLP-1R in pancreatic beta cells (insulin secretagogue, glucose-dependent), GI tract (gastric emptying modulation), and CNS satiety centers. The degree of effect is exposure-dependent and increases with dose escalation.
- Pyridoxine (B6): Cofactor in neurotransmitter biosynthesis; attenuates GI nausea via serotonergic modulation, with a well-established clinical record as an antiemetic for nausea syndromes.
Indications context: The 1 mg compounded orforglipron + B6 capsule is targeted to adults initiating GLP-1R agonist therapy who are especially GI-sensitive, re-initiating after prior intolerance, or following an extended titration protocol for maximal adherence. The ultra-low starting dose supports the prescriber's goal of long-term retention on therapy.
Prescriber monitoring considerations:
- Baseline metabolic panel, HbA1c, weight, renal function at therapy initiation.
- Clinical check-in at 4–8 weeks to evaluate GI tolerance and determine whether to advance the dose.
- Monitor for volume depletion signs in patients with baseline GI motility disorders or poor oral intake.
- Adjust concurrent insulin or secretagogue doses if glycemic response is unexpectedly significant at low doses (rare).
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
- Known hypersensitivity to orforglipron or any component
Warnings & Precautions:
- Thyroid C-cell tumors: class GLP-1R agonist warning; human clinical significance not established
- Pancreatitis: evaluate if severe abdominal pain develops
- GI adverse effects: nausea, decreased appetite — typically minimal at 1 mg but possible
- Acute kidney injury: secondary to GI dehydration in susceptible patients
Drug Interactions:
- Insulin/sulfonylureas: monitor for hypoglycemia (low risk at 1 mg)
- Gastric emptying delay: may affect narrow therapeutic index oral drug absorption even at low doses
Common Side Effects: Mild nausea, decreased appetite, and mild GI discomfort — typically minimal at the 1 mg dose. Pyridoxine co-formulation further attenuates GI onset effects.
Store at controlled room temperature (20–25°C / 68–77°F), protected from light and moisture, in the original dispensing container. Do not freeze. Follow the beyond-use date on the label assigned by Genesis Compounding. Keep out of reach of children.
Is 1 mg enough to do anything?
At 1 mg, the primary goal is GI acclimation, not maximal therapeutic effect. GLP-1 receptor agonist therapy requires dose escalation over weeks to months to reach effective doses. Starting at 1 mg minimizes the nausea and GI intolerance that can derail therapy, ensuring you reach and maintain the therapeutic dose.
How do I know when I am ready to increase the dose?
Your prescriber will assess your tolerability and clinical response at follow-up visits — typically every 4–8 weeks — and determine the escalation timing. Do not self-adjust the dose.
Why take B6 with such a low dose?
Even low-dose GLP-1R agonists can produce mild nausea in sensitive individuals. Pyridoxine is included proactively to minimize this from the first dose, supporting the best possible start to therapy.
Do I need blood tests while on this medication?
Yes — your prescriber will monitor blood glucose, HbA1c, kidney function, and weight at scheduled intervals. Baseline labs are typically obtained before starting and reassessed as you progress through the titration.
Is this FDA-approved?
Orforglipron received FDA approval in April 2026. This 1 mg + B6 compounded capsule is a prescriber-directed, patient-specific 503A preparation by Genesis Compounding and is not FDA-approved as a compounded product.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.